Abstract
Conditions in which serum or tissue acrolein levels are high (e.g.: renal failure, heavy smoking, oxidative stress) are also associated with increased thrombogenicity. Another emerging cardiovascular risk factor is homocysteine, and its derivative, homocysteine thiolactone. Antithrombin is one of the most important inhibitors of blood coagulation Since its activation by heparin binding requires critical interactions involving 3 Lys residues; we hypothesized that acrolein or homocysteine thiolactone impair antithrombin activity. When we incubated human antithrombin with increasing concentrations of acrolein (0-2 mmol/L) over a short period of time (0-4 h), a time and concentration dependent loss of activity was apparent (IC(50)=0.25 mmol/L). At 2 mmol/L, maximum inhibition (60%) is achieved at 1 h. This loss of activity was mirrored by changes in the electrophoretic pattern (homogeneity of the native antithrombin band as well as polymerization). In the same conditions, homocysteine thiolactone produces a significant, yet far less pronounced effect; acrolein being 3 times more potent than homocysteine thiolactone. When antithrombin was co-incubated with acrolein and cysteine, only less than 10% of antithrombin activity was lost. ...Continue Reading
References
Nov 1, 1974·Thrombosis Research·M BlombäckL Svendsen
Jan 1, 1994·Seminars in Thrombosis and Hemostasis·R L Bick, M Pegram
Jun 20, 1998·The Journal of Biological Chemistry·K UchidaE Niki
Aug 31, 2000·Toxicological Sciences : an Official Journal of the Society of Toxicology·J P Kehrer, S S Biswal
Dec 1, 2001·Archives of Internal Medicine·R H Thomas
Apr 4, 2003·Life Sciences·A Gugliucci, T Menini
Mar 23, 2005·Current Opinion in Pharmacology·Max NieuwdorpHarry Büller
Jul 23, 2005·Annals of the New York Academy of Sciences·Baohai ShaoJay W Heinecke
Aug 23, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xu YangRutai Hui
Aug 30, 2005·The Journal of Biological Chemistry·Baohai ShaoJay W Heinecke
Oct 1, 2005·Bioscience, Biotechnology, and Biochemistry·Hirofumi AraiKazuyuki Nakamura
Nov 9, 2005·Vascular Pharmacology·Dev B BaruahS S Kadam
Dec 3, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Wulf Dröge
Jan 3, 2006·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Denis BreuilléChristiane Obled
Feb 8, 2006·Environmental Toxicology·Kazutoshi Fujioka, Takayuki Shibamoto
Feb 16, 2006·Clinical Chemistry and Laboratory Medicine : CCLM·Chinhnam HathucAlejandro Gugliucci
Feb 24, 2006·Biochemistry·Derrick L SaulsMaureane Hoffman
Sep 16, 2006·The Journal of Biological Chemistry·Daniel J D JohnsonJames A Huntington
Dec 2, 2006·Thrombosis and Haemostasis·Rolf Dario FrankNigel Mackman
Jan 6, 2007·The Journal of Pharmacology and Experimental Therapeutics·André Tanel, Diana A Averill-Bates
Mar 17, 2007·Current Hypertension Reports·Carlos Mercado, Edgar A Jaimes
Jun 22, 2007·Biochemistry·Shiori Tamamizu-KatoVasanthy Narayanaswami
Jun 23, 2007·Current Pharmaceutical Design·Aurelio Leone
Jul 17, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Alejandro GugliucciSatoshi Kimura
Nov 1, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·Alejandro GugliucciSatoshi Kimura
Citations
Nov 4, 2008·Platelets·B OlasB Wachowicz
Sep 5, 2009·FEBS Letters·I Martínez-MartínezJ Corral
Jan 27, 2015·Thrombosis Research·S ValadeE Azoulay
Aug 2, 2011·Molecular Nutrition & Food Research·Giancarlo AldiniMarina Carini
Feb 16, 2011·Journal of Thrombosis and Haemostasis : JTH·L L SwystunP C Liaw
Jun 30, 2011·Molecular Nutrition & Food Research·Qin ZhuMingfu Wang
Jun 11, 2014·Biopolymers·Yulia Y StroylovaVladimir I Muronetz
Jun 25, 2013·Free Radical Biology & Medicine·Oren RomAbraham Z Reznick
May 23, 2012·Journal of Muscle Research and Cell Motility·Oren RomAbraham Z Reznick